Scholarlink

Background <p>Hematopoietic stem cell transplantation (HSCT) is a critical treatment for non-Hodgkin lymphoma (NHL) but involves significant post-transplant risks. Frailty, measured by the Modified Frailty Index-11 (mFI-11), may influence outcomes.</p> Methods <p>We analyzed NHL patients undergoing autologous or allogeneic HSCT from the Nationwide Inpatient Sample (2016–2020). Frailty was defined by mFI-11, and outcomes included in-hospital mortality, unfavorable discharge, prolonged length of stay (LOS), complications, and costs. Multivariable regression models with stratification by age and Charlson Comorbidity Index were applied.</p> Results <p>Of 2807 patients (ages 18–85), frail patients were older and had more comorbidities. In autologous HSCT, frailty was linked to higher mortality (2.02% vs. 0.27%, <i>p</i> &lt; 0.001), increased unfavorable discharges (19.75% vs. 10.80%, <i>p</i> &lt; 0.0001), and prolonged LOS (15.92% vs. 7.75%, <i>p</i> &lt; 0.0001). Similar trends were observed in the allogeneic cohort.</p> Conclusions <p>Frailty predicts worse post-transplant outcomes in NHL patients undergoing HSCT, emphasizing the need for pre-transplant frailty screening.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Modified Frailty Index-11 (mFI-11) measured frailty as a predictor of post-transplant outcomes in non-Hodgkin’s lymphoma patients undergoing hematopoietic stem cell transplantation: a retrospective analysis of National Inpatient Sample database

  • 期刊论文

  • 发表日期：

    2026年5月4日

查看全文
  • Abdul Hadi Khan,
  • Juan Nicolás Diaz-Riaño,
  • Eman Ijaz,
  • Aliu Olalekan Olatunji,
  • Mohammad Ahmmad Mahmoud Al Zoubi,
  • Almothana Altamimi,
  • Kaodichimma Dickson Fidelugwuowo,
  • Syed Owais Akhtar

摘要

Background

Hematopoietic stem cell transplantation (HSCT) is a critical treatment for non-Hodgkin lymphoma (NHL) but involves significant post-transplant risks. Frailty, measured by the Modified Frailty Index-11 (mFI-11), may influence outcomes.

Methods

We analyzed NHL patients undergoing autologous or allogeneic HSCT from the Nationwide Inpatient Sample (2016–2020). Frailty was defined by mFI-11, and outcomes included in-hospital mortality, unfavorable discharge, prolonged length of stay (LOS), complications, and costs. Multivariable regression models with stratification by age and Charlson Comorbidity Index were applied.

Results

Of 2807 patients (ages 18–85), frail patients were older and had more comorbidities. In autologous HSCT, frailty was linked to higher mortality (2.02% vs. 0.27%, p < 0.001), increased unfavorable discharges (19.75% vs. 10.80%, p < 0.0001), and prolonged LOS (15.92% vs. 7.75%, p < 0.0001). Similar trends were observed in the allogeneic cohort.

Conclusions

Frailty predicts worse post-transplant outcomes in NHL patients undergoing HSCT, emphasizing the need for pre-transplant frailty screening.